All In Biotech

Drug Trial Radar · NCT03151551

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

Last checked: Nov 20, 2026Latest source record: Nov 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 566 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

566

Actual

Start

Aug 24, 2017

Primary completion

Nov 15, 2018

Study completion Sep 4, 2019

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
May 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

Conditions

  • Psoriatic Arthritis

Interventions

  • IxekizumabDrug

    Administered SC

  • AdalimumabDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)Time frame: Week 24

Locations

131 sites in 22 countries. Site status is shown where the registry gives one.

  • Organizacion Medica de Investigacion - OMI

    Ciudad Autonoma de Buenos Aire, Argentina

  • Instituto Centenario

    Ciudad Autonoma de Buenos Aire, Argentina

  • Hospital Ramos Mejia

    Ciudad Autonoma de Buenos Aire, Argentina

  • Centro de Medicina Familiar Mindout Research

    Ciudad Autonoma de Buenos Aire, Argentina

  • CENUDIAB

    Ciudad Autonoma de Buenos Aire, Argentina

  • Consultora Integral de Salud S.R.L.

    Córdoba, Argentina

  • Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan

    San Juan, Argentina

  • Atencion Integral en Reumatología

    Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

  • Clinica Adventista de Belgrano

    Ciudad de Buenos Aires, Buenos Aires, Argentina

  • CER Instituto Medico

    Quilmes, Buenos Aires, Argentina

  • Instituto de Asist Reumatologica Integral

    San Fernando, Buenos Aires, Argentina

  • Centro Medico Privado de Reumatologia

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Combined Rheumatology Practice (CRP)

    Kogarah, New South Wales, Australia

  • Rheumatology, The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Southern Clinical Research Pty Ltd

    Hobart, Tasmania, Australia

  • Emeritus Research

    Camberwell, Victoria, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Zentrum für klinische Studien Dr. Ursula Hanusch GmbH

    Vienna, Austria

  • AKH

    Vienna, Austria

  • Rheuma-Zentrum Wien Oberlaa

    Vienna, Austria

  • Reumaclinic

    Genk, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Saint Joseph Hospital

    Gilly, Belgium

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Hopital Ambroise Pare

    Mons, Belgium

  • Group de recherche en maladies osseuses

    Québec, Canada

  • The Waterside Clinic

    Barrie, Ontario, Canada

  • SKiN Center for Dermatology

    Peterborough, Ontario, Canada

  • Centre de Recherche Musculo-Squelettique

    Trois-Rivières, Quebec, Canada

  • Polmed Research Inc.

    Saskatoon, Saskatchewan, Canada

  • Aalborg Universitetshospital - Psykiatrien

    Aalborg, Denmark

  • Frederiksberg Hospital

    Frederiksberg, Capital Region, Denmark

  • Helsinki University Hospital, HYKS

    Helsinki, Finland

  • Kiljava Medical Research

    Hyvinkää, Finland

  • Terveystalo Kouvola

    Kouvola, Finland

  • Turun Yliopistollinen Keskussairaala

    Turku, Finland

  • Hôpital Trousseau, CHRU de Tours

    Chambray-lès-Tours, France

  • Centre Hospitalier de Vendee Les Oudairies

    La Roche-sur-Yon, France

  • Hopital Edouard Herriot

    Lyon, France

  • Centre hospitalier universitaire Lapeyronie

    Montpellier, France

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.